Azitra, Inc. Announces Presentation at the 2025 BIO International Convention

Rhea-AI Summary

Azitra (NYSE American: AZTR), a clinical stage biopharmaceutical company specializing in precision dermatology, will present at the 2025 BIO International Convention in Boston from June 16-19. The company's COO and Cofounder, Travis Whitfill PhD MPH, will present on June 17 at 12:00 PM ET, focusing on pipeline updates including ATR-12 (in Phase 1b trials for Netherton syndrome) and ATR-04 (in development for EGFRi-associated dermal toxicity). Dr. Whitfill will also conduct one-on-one meetings with investors and potential partners to discuss business strategy, corporate achievements, and upcoming milestones.

BRANFORD, Conn., June 10, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the company will present at the BIO International Convention being held June 16-19, 2025, in Boston, Massachusetts.

The presentation will highlight recent updates and progress in Azitra's pipeline, including ATR-12, currently in a Phase 1b clinical trial in adult patients with Netherton syndrome and ATR-04, in development for the treatment of moderate to severe EGFRi-associated dermal toxicity in adults.

Details of the presentation are as follows:

Event:	2025 BIO International Convention
Date and Time:	Tuesday, June 17 at 12:00 PM, ET
Location:	Boston Convention & Exhibition Center, Room 154
Presenter:	Travis Whitfill PhD MPH, Cofounder and Chief Operating Officer

During the conference, Dr. Whitfill will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's business and clinical development strategy, recent corporate achievements, and anticipated milestones. 

About Azitra, Inc.

Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. The Company's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome may be fatal in infancy with those living beyond a year having profound lifelong challenges. The ATR-12 program includes a Phase 1b clinical trial in adult Netherton syndrome patients. ATR-04, Azitra's additional advanced program, utilizes another engineered strain of S. epidermidis for the treatment of EGFR inhibitor ("EGFRi") associated rash. Azitra has received Fast Track designation from the FDA for EGFRi associated rash, which impacts approximately 150,000 people in the U.S. Azitra has an open IND for its ATR-04 program in patients with EGFRi associated rash. The ATR-12 and ATR-04 programs were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic products that includes a microbial library comprised of approximately 1,500 bacterial strains. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the library of strains for drug like molecules. For more information, please visit https://azitrainc.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the expected timing of the abstract detailing the Phase 1/2 clinical trial for our ATR-04 program, the initiation of dosing in the Phase 1/2 clinical trial for our ATR-04 program, and statements about our clinical and preclinical programs, and corporate and clinical/preclinical strategies.

Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to that we may fail to present this abstract detailing the Phase 1/2 clinical trial or, if we are able to do so, that the abstract will be favorably received; we may experience delays in the dosing the first patient in this Phase 1/2 trial; our product candidates may not be effective; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra's programs and operations are described or incorporated by reference in our annual report on Form 10-K filed with the SEC on February 24, 2025. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact

Norman Staskey
Chief Financial Officer
staskey@azitrainc.com

Investor Relations
Tiberend Strategic Advisors, Inc.
Jon Nugent
205-566-3026
jnugent@tiberend.com  

Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/azitra-inc-announces-presentation-at-the-2025-bio-international-convention-302477576.html

SOURCE Azitra, Inc.

FAQ

When is Azitra (AZTR) presenting at the 2025 BIO International Convention?

Azitra is presenting on Tuesday, June 17, 2025, at 12:00 PM ET at the Boston Convention & Exhibition Center, Room 154.

What clinical trials is Azitra (AZTR) currently conducting?

Azitra is conducting a Phase 1b clinical trial for ATR-12 in adult patients with Netherton syndrome and developing ATR-04 for moderate to severe EGFRi-associated dermal toxicity in adults.

Who will be presenting for Azitra (AZTR) at the 2025 BIO Convention?

Travis Whitfill PhD MPH, Cofounder and Chief Operating Officer of Azitra, will be presenting at the convention.

What will be discussed at Azitra's (AZTR) BIO Convention presentation?

The presentation will cover recent updates and progress in Azitra's pipeline, business and clinical development strategy, recent corporate achievements, and anticipated milestones.